GSK-Partnered Alector Hit By Renewed Dementia Skepticism
Doubts About Biomarker
Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker
You may also be interested in...
Denali Therapeutics has reported promising early clinical data in Hunter syndrome for its fusion protein, DNL310, an investigational agent that crosses the blood-brain barrier and is expected to address disease-associated CNS effects; however, some biomarker data disappointed, and there are potential competitors also under development.
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO
, and has underlined competitive threats to a key pipeline candidate.
The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.